Scancell

What Scancell does

Scancell is a late-stage clinical immuno-oncology company developing off-the-shelf active immunotherapies for cancer from four proprietary technology platforms: Immunobody® (DNA-based cancer vaccines), Moditope® (peptide-based neoantigen vaccines), GlyMab® (anti-glycan antibodies), and AvidiMab® (Fc engineering). Its lead candidate, iSCIB1+, is a needle-free DNA immunotherapy combined with checkpoint inhibitors for advanced melanoma, which has reported 77% progression-free survival at 20 months versus 43% for standard ipilimumab plus nivolumab in a Phase 2 SCOPE trial, received FDA Fast Track Designation in April 2026, and is positioned to start a global Phase 3 registrational trial in Q3 2026. Secondary assets include the Modi-1 peptide vaccine in Phase 1/2 (ModiFY) for solid tumours including renal cell carcinoma, the Modi-2 pan-cancer vaccine in preclinical work, and SC134 (a GlyMab® T cell engager for small cell lung cancer) moving to IND-enabling studies. Two GlyMab® antibodies have been licensed to Genmab, providing the company's main external commercial relationship, and SCIB1/iSCIB1+ is delivered via the PharmaJet Stratis® needle-free system with UK patient access enabled by the NHS Cancer Vaccine Launch Pad.

The business model is pre-revenue and clinical-stage, with the company explicitly stating it has no current commercial products and anticipates revenue only upon regulatory approval and commercialization of iSCIB1+ and Modi-1. The monetization pathway combines (i) future product sales of iSCIB1+ and Modi-1 in melanoma and solid tumour indications; (ii) licensing royalties and milestone payments from Genmab on the GlyMab® portfolio; and (iii) potential additional antibody and platform out-licensing from a fully resourced business development function. The company is publicly listed on AIM (LSE: SCLP) with a 1,037,781,403 ordinary share base, has raised roughly £10.7 million in December 2023 and £10.3 million in December 2024 to fund the pipeline (cash runway into H2 2026), and is in advanced discussions for a reverse merger with Neuphoria Therapeutics that would provide a Nasdaq listing and additional Phase 3 financing. Customers today are clinical trial sites and research hospitals rather than paying end customers, with NHS and named UK cancer centres serving as recruitment and access channels.

Name

Scancell

Legal name

Scancell Holdings PLC

Website

https://scancell.co.uk

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Scancell is a pre-revenue, UK-listed clinical-stage immuno-oncology company developing off-the-shelf active cancer immunotherapies (DNA, peptide, and antibody platforms) led by iSCIB1+ for advanced melanoma, licensed to Genmab on its antibody platform and advancing toward a global Phase 3.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Cancer immunotherapy
• Immuno-oncology vaccines
• Monoclonal antibody therapeutics
• DNA cancer vaccines
• Peptide cancer vaccines

Headquarters

HQ city

Nottingham

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Royalties: Scancell generates revenue through licensing agreements with partners such as Genmab for GlyMab® antibodies, with potential milestone payments and royalties on commercialized products.
2. Pharmaceutical Development: Pre-revenue clinical-stage company developing cancer immunotherapies with no current commercial products. Anticipates generating revenue upon regulatory approval and commercialization of iSCIB1+ and Modi-1.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Scancell develops off-the-shelf active immunotherapies for cancer treatment through four proprietary platforms: Immunobody® (DNA-based vaccines), Moditope® (peptide-based vaccines), GlyMab® (anti-glycan antibodies), and AvidiMab® (Fc engineering). Its lead clinical asset iSCIB1+ is a DNA immunotherapy for advanced melanoma currently in Phase 3 development with FDA Fast Track Designation, designed for needle-free administration combined with checkpoint inhibitors.

Product overview

Scancell is a late-stage clinical immuno-oncology company developing a portfolio of off-the-shelf active immunotherapies from two proprietary technology platforms: Immunobody® (DNA-based cancer vaccines) and Moditope® (peptide-based cancer vaccines). The lead product is iSCIB1+, an Immunobody® DNA immunotherapy for advanced melanoma entering Phase III, combined with checkpoint inhibitors. The Modi-1 peptide vaccine is in Phase 2 for solid tumours. The company also has a GlyMab® antibody platform with two candidates licensed to Genmab, and an AvidiMab® Fc engineering technology. All pipeline products are designed to be off-the-shelf, patient-accessible treatments with favourable safety profiles.

Differentiator

Problem solved

Functional benefit

Brands

• GlyMab: GlyMab platform - high affinity antibodies targeting tumour specific glycans, developed by Glymab Therapeutics Ltd.
• AvidiMab
• ImmunoBody
• Moditope

Products and services

• iSCIB1+ Lead Immunobody® DNA active immunotherapy candidate for advanced melanoma. A needle-free, tumour-targeted, off-the-shelf immunotherapy entering Phase III trials, designed to generate potent and lasting immune responses when combined with checkpoint inhibitors.
• SCIB1 Earlier version of Immunobody® DNA vaccine incorporating approximately half the melanoma-specific epitopes of iSCIB1+. Demonstrated monotherapy activity in adjuvant melanoma and efficacy in combination with checkpoint inhibitors.
• Modi-1 Lead Moditope® peptide active immunotherapy targeting citrullinated peptides. An off-the-shelf, tumour-specific neoantigen therapy administered alone or with checkpoint inhibitors in solid tumours including renal cell carcinoma.
• Modi-2 Vaccine from Moditope® platform targeting stress-induced post translational modifications (siPTMs) such as homocitrullination, offering an off-the-shelf pan-cancer vaccine approach.
• SC134 Lead GlyMab® candidate being developed as a T cell engager for small cell lung cancer (SCLC), targeting FucosylGM1. Ready to move into IND-enabling studies.

Quantifiable outcome

• 77% progression-free survival at 20 months for iSCIB1+ combination therapy vs 43% for standard care (ipilimumab + nivolumab)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Neuphoria Therapeutics IncflagshipStrategic or Co-development Partner · 26 June 2026Advanced discussions for potential all-share reverse merger transaction that would enable Scancell to list on Nasdaq via reverse merger structure. Also discussing equity and debt financing for global Phase III trial of iSCIB1+.
• NHS Cancer Vaccine Launch Pad (CVLP)coreStrategic or Co-development Partner · 14 April 2025Partnership with NHS enabling fast-tracked access for melanoma patients to participate in Scancell's clinical trials, accelerating patient recruitment and providing early access pathway.
• PharmaJetcoreStrategic or Co-development Partner · 17 September 2024Strategic partnership for use of PharmaJet's Stratis® IM Needle-free delivery system in the development and administration of SCIB1/iSCIB1+ cancer vaccine for advanced melanoma.
• Genmab A/ScoreOEM/ Whitelabel/ Licensing Partner · 25 October 2022Genmab has licensed two GlyMab® antibodies from Scancell and exercised option to a second commercial license agreement. Genmab is a global leader in antibody therapeutics developing these candidates for solid cancer applications.
• University of NottinghamcoreStrategic or Co-development PartnerScancell was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham. Ongoing relationship for research and academic collaboration with Professor Durrant holding a personal Chair in Cancer Immunotherapy in the Department of Clinical Oncology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• BioNTech: Develops mRNA-based cancer vaccines including BNT122 (autogene cevumeran) for melanoma and other solid tumors. Directly comparable to Scancell as a cancer vaccine developer targeting similar indications with overlapping neoantigen and active immunotherapy approaches.
• Moderna: Through its mRNA-4157/V940 personalized neoantigen vaccine (partnered with Merck), Moderna is a direct competitor in the melanoma adjuvant and advanced setting against which Scancell's iSCIB1+ will compete commercially and clinically.
• Gritstone bio: Develops neoantigen-based cancer vaccines (GRT-C901/GRT-C903) targeting shared and personalized tumor neoantigens. Direct peer to Scancell in the active immunotherapy cancer vaccine category with similar mechanism targeting MHC presentation.
• Nouscom: Private clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vectors. Highly comparable to Scancell's off-the-shelf DNA/peptide vaccine platforms and clinical-stage positioning.
• CureVac: mRNA technology company developing cancer vaccines including off-the-shelf and personalized neoantigen approaches. Comparable to Scancell as a cancer vaccine developer at the intersection of mRNA and active immunotherapy.

Broad incumbents

• Immunocore: Commercial-stage UK immuno-oncology company with approved TCR-based therapy (Kimmtrak) and broader T cell receptor pipeline. Comparable to Scancell as a UK-based immuno-oncology company with overlapping T cell-targeting biology and melanoma indications.
• Adaptimmune Therapeutics: Commercial and clinical-stage TCR cell therapy company (Tecelra) developing engineered T cell therapies for solid tumors including melanoma. Comparable to Scancell as a UK-based clinical-stage immuno-oncology company targeting similar solid tumor indications.
• Bristol-Myers Squibb: Maker of ipilimumab (Yervoy) and nivolumab (Opdivo), the standard-of-care checkpoint inhibitor combination Scancell's iSCIB1+ is being tested against. The dominant incumbent in advanced melanoma CPI combinations and the principal comparator in Scancell's clinical strategy.
• Genmab A/S: Global antibody therapeutics leader and a Scancell partner (licensee of GlyMab antibodies). Comparable as a developer of antibody-based oncology therapeutics and as Scancell's principal commercial-stage antibody validation partner.

Emerging players

• Achilles Therapeutics: Clinical-stage UK biotech developing personalized neoantigen T cell therapies for solid tumors including non-small cell lung cancer and melanoma. Comparable to Scancell in cancer antigen-targeting immunotherapy with overlapping UK clinical-stage positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/scancellpharma
• LinkedInlinkedin.com/company/scancell-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scancell